| Useful Advices |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Top7 or 10 Tips > Measuring Remote/Flexible Working Projects: The Top 7 Performance Indicators |
|
Useful Advices - Measuring Remote/Flexible Working Projects: The Top 7 Performance Indicators
Many organisations are currently investing in remote and flexible working practices in order to reduce operating costs, improve team efficiency and make smarter, more efficient use of corpo According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product rate accommodation. This article describes the top 7 things that should be measured in assessing the long term performance of your strategy. We would suggest that scores are assigned to t ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in e following 7 key areas regarding a team efficiency at the start of the change programme, then after 3 months and after a year. It is difficult to gain an insightful appreciation of the act lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ual impact of something when you are 'on the ground'. Being able to refer back to a documented record of prior performance and predicted/actual impact of a change can give a much truer pict here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe re. 1. Productivity There are many factors which make up the 'productivity' impact of the introduction of remote working. How long does it take to carry out the business d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro process compared to the 'old school' method', quantity and quality of team collaboration ? What level of control does the team leader have now they are not in the same location as the tea ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc members. 2. Quality of Information Centralisation of data is key to ensuring maximum benefit in this area. Any duplicate entry of key corporate data locally will introdu easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ce additional human error. If an increase in error/poor quality work is a major concern, data duplication and synchronisation solutions should be investigated as well as the use of web serv nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ces to provide secure access to centralised data systems. 3. Speed Of Response Access to information is key to the effectiveness of remote and mobile work practices. The and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ availability of the right data at the right time to the right members of staff. Security concerns will remain central to some industry sectors and therefore the availability of data need to ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi be balanced against the approach taken to authentication and user roles and permissions. 4. Systems Acceptance and Usage By Staff Simplicity of user interaction, immediac ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a y of the right information to the right individuals and sufficient appropriate training and education will combine to either create a solution which is accepted and adds value to the emplo dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ees or one that is despised by employees and avoided at all costs. 5. Return of Investment The bottom line here is that any investment needs to be justified. For revised cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin patterns of working, innovative communication technology or education and expert external consultancy in mobile/remote working should be no exception. 6. Customer Satisfaction Per tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen eption Where the service provided by the teams involved are customer/consumer facing it is important to measure customer satisfaction levels before and after the change of practic t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel es. Our evidence has been that although savings have been made in other areas and teams efficiency can be improved - that with careful handling customer service levels can be sustained. ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust rong>7. Staff Perception The impact of a change of working practice and associated adjustments to a revised way of doing things can have a profound impact of personnel. It is impo y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products rtant to understand the initial perception of staff prior to the introduction of any changes, ensure that they are well informed and provided the necessary training throughout the programm . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de and given and robust readily available mechanism for passing back feedback during the process. In summary, there are a key set of delivered objectives and milestones which should be consi elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip dered during the process of remote/flexible working adoption and careful thought should be given prior during and after implementation in order to ensure that maximum benefits are achieved tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Your Fees - It's About Value - Not Time
|